Cuprina Holdings (Cayman) LTD (ticker: CUPR) is an NASDAQ-listed clinical biotech company. DredgeCap's structured extraction of CUPR's SEC filings surfaces 2 active risk signals, including 1 auditor-change signal, and 1 late-filing signal. CUPR reported $39K in revenue and -$3.63M for the period ending 2025-12-31, with operating cash flow of -$7.10M. Cash and equivalents stood at $2.42M (up 2730.8% year-over-year). Total assets of $6.61M exceed total liabilities of $2.68M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
CUPR Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Cuprina Holdings (Cayman) LTD (CUPR) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.